Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial

Archives of Cardiovascular Diseases

Volumn 102, Issue 2, 2009, Pages 89-96

  Bertrand, Michel E ^a   Fox, Kim M ^b   Remme, Willem J ^c   Ferrari, Roberto ^d   Simoons, Maarten L ^e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Sticares Cardiovascular Research Foundation   (Netherlands)

^d UNIVERSITY OF FERRARA   (Italy)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitor; Coronary artery disease; Myocardial infarction; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; PERINDOPRIL; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT;

EID: 64249148964     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.10.012     Document Type: Article

References (14)

1. Murray C. Ischemic heart disease. In: Murray C, Lopez A, editors. The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injury and risk factors in 1990 and projected to 2020. Cambridge (Ma): Harvard University Press; 1996.
2. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
3. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
4. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
6. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006;47:1576-83.
7. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricutar systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
8. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166: 787-96.
9. Fox KM, Bertrand ME, Remme WJ, Ferrari R, Simoons ML, Deckers JW. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J 2007;153:629-35.
10. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
11. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-8.
12. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
13. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008;117:24-31.
14. Lau CP, Tse HF, Ng W, et al. Comparison of perindopril versus captopril for treatment of acute myocardial infarction. Am J Cardiol 2002;89:150-4.